Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.

Abstract

Mitochondrial dysfunction plays a major role in the pathogenesis of Parkinson disease (PD). Creatine (Cr) is an ergogenic compound that exerts neuroprotective effects in animal models of PD. We conducted a 2-year placebo-controlled randomized clinical trial on the effect of Cr in 60 patients with PD. Cr improved patient mood and led to a smaller dose increase of dopaminergic therapy but had no effect on overall Unified Parkinson's Disease Rating Scale scores or dopamine transporter SPECT.

• Authors: A Bender, W Koch, M Elstner, Y Schombacher, J Bender, M Moeschl, F Gekeler, B Müller-Myhsok, T Gasser, K Tatsch, T Klopstock
• Journal: Neurology (Neurology) Vol. 67 Issue 7 Pg. 1262-4 (Oct 10 2006) ISSN: 1526-632X [Electronic] United States
• PMID: 17030762 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Creatine

Topics

• Administration, Oral
• Brain (diagnostic imaging, drug effects)
• Creatine (administration & dosage)
• Dietary Supplements
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Parkinson Disease (diagnostic imaging, drug therapy)
• Pilot Projects
• Placebo Effect
• Radionuclide Imaging
• Treatment Outcome